Learnings from clinical trials in patients with connective tissue disease-associated interstitial lung disease.
Learnings from clinical trials in patients with connective tissue disease-associated interstitial lung disease.
复制标题
DOI：
10.1186/s13075-023-03090-y
复制
发表时间：
2023-07-08
影响因子：
4.9
通讯作者：
中科院分区：
文献类型：
--
作者：
许多临床试验结果可用于指导结缔组织病相关间质性肺病（CTD-ILD）患者的最佳治疗实践。在此，我们总结了临床试验的结果，包括患者报告的结果工具，用于治疗与系统性硬化症（SSc/硬皮病）、类风湿性关节炎和特发性炎性肌炎相关的ILD患者，这些疾病的数据最多。对于SSc-ILD，美国食品药品监督管理局于2020年批准了尼达尼布（一种酪氨酸激酶抑制剂），并于2021年批准了皮下注射托珠单抗（一种IL-6受体单克隆抗体）。最近显示利妥昔单抗治疗CTD-ILD的疗效与静脉内环磷酰胺（CYC）相似，但耐受性更好。在SSc-ILD患者中进行的硬皮病肺研究II显示，口服CYC和霉酚酸酯（MMF）对肺功能的影响相当，但MMF的耐受性更好。CTD-ILD患者的治疗设备不断增加，为医生提供了改善患者结局的新机会。
Many clinical trial results are available to inform best practices in the treatment of patients with connective tissue disease-associated interstitial lung disease (CTD-ILD). Herein, we summarize the results of clinical trials, including patient-reported outcome instruments, for the treatment of patients with ILD associated with systemic sclerosis (SSc/scleroderma), rheumatoid arthritis, and idiopathic inflammatory myositis, the diseases with the most available data. For SSc-ILD, the US Food and Drug Administration approved nintedanib (a tyrosine kinase inhibitor) in 2020 and subcutaneous tocilizumab (an IL-6 receptor monoclonal antibody) in 2021. Rituximab was recently shown to have similar efficacy but better tolerability than intravenous cyclophosphamide (CYC) for CTD-ILD therapy. Scleroderma Lung Study II, conducted in patients with SSc-ILD, showed that oral CYC and mycophenolate mofetil (MMF) were comparable in their effects on lung function, but MMF was better tolerated. The increasing treatment armamentarium for patients with CTD-ILD offers physicians new opportunities to improve patient outcomes.
登录
查看更多内容
影响因子：
4.8
作者：
Del Papa, N.;Onida, F.;Cortelezzi, A.
通讯作者：
Cortelezzi, A.
影响因子：
158.5
作者：
Distler, Oliver;Highland, Kristin B.;Maher, Toby M.
通讯作者：
Maher, Toby M.
影响因子：
3.1
作者：
Ando, Katsutoshi;Motojima, Shinji;Takahashi, Kazuhisa
通讯作者：
Takahashi, Kazuhisa
影响因子：
27.4
作者：
通讯作者：
--
影响因子：
8.9
作者：
Crespo, Maria M.;Lease, Erika D.;Budev, Marie
通讯作者：
Budev, Marie